Braveheart Investment Group plc (AIM: BRH) provides the following update on Phasefocus and Paraytec, companies within the Group’s investment portfolio.
Braveheart Investment Group plc (AIM: BRH) provides the following update on Phasefocus and Paraytec, companies within the Group’s investment portfolio.
Perhaps the best thing about the Government’s present woes as far as small caps are concerned is that we are already bumping along the bottom, or at least hope that
Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update
Poolbeg Pharma commences trading on OTCQB Market in the United States
First time that AI analysis of human challenge trial data is used to identify novel drug targets for influenza
9 March 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical-stage infectious disease pharmaceutical company with a unique capital-light clinical model, announces that its Annual Report and
Braveheart Investment Group plc (AIM: BRH), provides the following update on its investment portfolio and strategy.
31 January 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical-stage infectious disease pharmaceutical company with a capital-light clinical model, confirms that it has signed the licence
Braveheart Investment Group plc (AIM: BRH), is pleased to provide the following update on Paraytec, a company within the Group’s investment portfolio. Recent upgrades to the CX300 instrument indicate a
Poolbeg Pharma licences first-in-class broad spectrum RNA-based immunotherapy for respiratory virus infections from the University of Warwick
Targeting the growing infectious disease market, we are developing multiple assets quickly to Phase II ready with plans to monetise early to Big Pharma. POLB spun out of Open Orphan